Nirmal Bang: Sun Pharma’s Revenue Growth Helps Margin Expansion In Q2
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
Sun Pharmaceutical Industries Ltd.’s Q2 FY21 revenue at Rs 85,531 million is up 12.8% QoQ and 5.3% YoY given the easing of lockdowns across the world.
The highest ever quarterly revenue in the company’s history was driven by growth across geographies with rest of world markets and emerging markets growing the fastest on a QoQ basis.
We expect the revenue performance to sustain in subsequent quarters led by India business revival and ongoing ramp up in specialty portfolio.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.